Afficher la couverture 'Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients | Lioger, Bertrand' en grand format
/5

0 avis

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Archive ouverte

Lioger, Bertrand | Edupuganti, Soujanya Ratna | Mulleman, Denis | Passot, Christophe | Desvignes, Celine | Bejan-Angoulvant, Theodora | Thibault, Gilles | Gouilleux-Gruart, Valérie | Mélet, Julien | Paintaud, Gilles | Ternant, David

Edité par CCSD ; Wiley -

International audience. Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients.

Consulter en ligne

Suggestions

Du même auteur

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

Archive ouverte | Ternant, David | CCSD

International audience

Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials

Archive ouverte | Lioger, François | CCSD

International audience. To compare the efficacy and safety of intravenous immunoglobulins (IVIG) and anti-D immunoglobulin (anti-D) in pediatric immune thrombocytopenia (ITP).

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

Archive ouverte | Passot, Christophe | CCSD

International audience. Infliximab is an anti-tumor necrosis factor monoclonal antibody approved in chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis ...

Chargement des enrichissements...